FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893361531> ?p ?o ?g. }

• W2893361531 endingPage "1540" @default.
• W2893361531 startingPage "1530" @default.
• W2893361531 abstract "Previous studies showed more adverse events with coronary bioresorbable vascular scaffolds (BVS) than with metallic drug-eluting stents (DES), although in one randomised trial angina was reduced with BVS. However, these early studies were unmasked, lesions smaller than intended for the scaffold were frequently enrolled, implantation technique was suboptimal, and patients with myocardial infarction, in whom BVS might be well suited, were excluded.In the active-controlled, blinded, multicentre, randomised ABSORB IV trial, patients with stable coronary artery disease or acute coronary syndromes aged 18 years or older were recruited from 147 hospitals in five countries (the USA, Germany, Australia, Singapore, and Canada). Enrolled patients were randomly assigned (1:1) to receive polymeric everolimus-eluting BVS (Absorb; Abbott Vascular, Santa Clara, CA, USA) with optimised implantation technique or cobalt-chromium everolimus-eluting stents (EES; Xience; Abbott Vascular, Santa Clara, CA, USA). Randomisation was stratified by diabetic status, whether patients would have been eligible for enrolment in the previous ABSORB III trial, and site. Patients and clinical assessors were masked to randomisation. The primary endpoint was target lesion failure (cardiac death, target vessel myocardial infarction, or ischaemia-driven target lesion revascularisation) at 30 days, tested for non-inferiority with a 2·9% margin for the risk difference. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT02173379, and is closed to accrual.Between Aug 15, 2014, and March 31, 2017, we screened 18 722 patients for eligibility, 2604 of whom were enrolled. 1296 patients were assigned to BVS, and 1308 patients were assigned to EES. Follow-up data at 30 days and 1 year, respectively, were available for 1288 and 1254 patients with BVS and for 1303 and 1272 patients with EES. Biomarker-positive acute coronary syndromes were present in 622 (24%) of 2602 patients, and, by angiographic core laboratory analysis, 78 (3%) of 2893 of lesions were in very small vessels. Target lesion failure at 30 days occurred in 64 (5·0%) patients assigned to BVS and 48 (3·7%) patients assigned to EES (difference 1·3%, upper 97·5% confidence limit 2·89; one-sided pnon-inferiority=0·0244). Target lesion failure at 1 year occurred in 98 (7·8%) patients assigned to BVS and 82 (6·4%) patients assigned to EES (difference 1·4%, upper 97·5% confidence limit 3·4; one-sided pnon-inferiority=0·0006). Angina, adjudicated by a central events committee at 1 year, occurred in 270 (20·3%) patients assigned to BVS and 274 (20·5%) patients assigned to EES (difference -0·3%, 95% CI -3·4% to 2·9%; one-sided pnon-inferiority=0·0008; two-sided psuperiority=0·8603). Device thrombosis within 1 year occurred in nine (0·7%) patients assigned to BVS and four (0·3%) patients assigned to EES (p=0·1586).Polymeric BVS implanted with optimised technique in an expanded patient population resulted in non-inferior 30-day and 1-year rates of target lesion failure and angina compared with metallic DES.Abbott Vascular." @default.
• W2893361531 created "2018-10-05" @default.
• W2893361531 creator A5007377189 @default.
• W2893361531 creator A5011403969 @default.
• W2893361531 creator A5012079171 @default.
• W2893361531 creator A5021512906 @default.
• W2893361531 creator A5026463075 @default.
• W2893361531 creator A5044224919 @default.
• W2893361531 creator A5044409518 @default.
• W2893361531 creator A5046629853 @default.
• W2893361531 creator A5054761754 @default.
• W2893361531 creator A5061176989 @default.
• W2893361531 creator A5066366880 @default.
• W2893361531 creator A5067465521 @default.
• W2893361531 creator A5070039427 @default.
• W2893361531 creator A5078133108 @default.
• W2893361531 creator A5082003758 @default.
• W2893361531 creator A5083494581 @default.
• W2893361531 creator A5084911580 @default.
• W2893361531 creator A5088608614 @default.
• W2893361531 creator A5089717361 @default.
• W2893361531 date "2018-10-01" @default.
• W2893361531 modified "2023-09-29" @default.
• W2893361531 title "Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial" @default.
• W2893361531 cites W2011505588 @default.
• W2893361531 cites W2054544120 @default.
• W2893361531 cites W2059110168 @default.
• W2893361531 cites W2099207046 @default.
• W2893361531 cites W2131110587 @default.
• W2893361531 cites W2136612769 @default.
• W2893361531 cites W2160414137 @default.
• W2893361531 cites W2172454067 @default.
• W2893361531 cites W2173994032 @default.
• W2893361531 cites W2250744360 @default.
• W2893361531 cites W2252647110 @default.
• W2893361531 cites W2259115522 @default.
• W2893361531 cites W2279719203 @default.
• W2893361531 cites W2337114878 @default.
• W2893361531 cites W2469160399 @default.
• W2893361531 cites W2492270531 @default.
• W2893361531 cites W2543693155 @default.
• W2893361531 cites W2598919558 @default.
• W2893361531 cites W2765992454 @default.
• W2893361531 cites W2766476338 @default.
• W2893361531 cites W2772883422 @default.
• W2893361531 cites W2795453893 @default.
• W2893361531 cites W4253686430 @default.
• W2893361531 doi "https://doi.org/10.1016/s0140-6736(18)32283-9" @default.
• W2893361531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30266412" @default.
• W2893361531 hasPublicationYear "2018" @default.
• W2893361531 type Work @default.
• W2893361531 sameAs 2893361531 @default.
• W2893361531 citedByCount "96" @default.
• W2893361531 countsByYear W28933615312018 @default.
• W2893361531 countsByYear W28933615312019 @default.
• W2893361531 countsByYear W28933615312020 @default.
• W2893361531 countsByYear W28933615312021 @default.
• W2893361531 countsByYear W28933615312022 @default.
• W2893361531 countsByYear W28933615312023 @default.
• W2893361531 crossrefType "journal-article" @default.
• W2893361531 hasAuthorship W2893361531A5007377189 @default.
• W2893361531 hasAuthorship W2893361531A5011403969 @default.
• W2893361531 hasAuthorship W2893361531A5012079171 @default.
• W2893361531 hasAuthorship W2893361531A5021512906 @default.
• W2893361531 hasAuthorship W2893361531A5026463075 @default.
• W2893361531 hasAuthorship W2893361531A5044224919 @default.
• W2893361531 hasAuthorship W2893361531A5044409518 @default.
• W2893361531 hasAuthorship W2893361531A5046629853 @default.
• W2893361531 hasAuthorship W2893361531A5054761754 @default.
• W2893361531 hasAuthorship W2893361531A5061176989 @default.
• W2893361531 hasAuthorship W2893361531A5066366880 @default.
• W2893361531 hasAuthorship W2893361531A5067465521 @default.
• W2893361531 hasAuthorship W2893361531A5070039427 @default.
• W2893361531 hasAuthorship W2893361531A5078133108 @default.
• W2893361531 hasAuthorship W2893361531A5082003758 @default.
• W2893361531 hasAuthorship W2893361531A5083494581 @default.
• W2893361531 hasAuthorship W2893361531A5084911580 @default.
• W2893361531 hasAuthorship W2893361531A5088608614 @default.
• W2893361531 hasAuthorship W2893361531A5089717361 @default.
• W2893361531 hasConcept C126322002 @default.
• W2893361531 hasConcept C141071460 @default.
• W2893361531 hasConcept C197934379 @default.
• W2893361531 hasConcept C203092338 @default.
• W2893361531 hasConcept C2776863835 @default.
• W2893361531 hasConcept C2777785093 @default.
• W2893361531 hasConcept C2778213512 @default.
• W2893361531 hasConcept C2778425758 @default.
• W2893361531 hasConcept C2778583881 @default.
• W2893361531 hasConcept C2779699572 @default.
• W2893361531 hasConcept C2780400711 @default.
• W2893361531 hasConcept C2781464078 @default.
• W2893361531 hasConcept C500558357 @default.
• W2893361531 hasConcept C535046627 @default.
• W2893361531 hasConcept C71924100 @default.
• W2893361531 hasConceptScore W2893361531C126322002 @default.
• W2893361531 hasConceptScore W2893361531C141071460 @default.
• W2893361531 hasConceptScore W2893361531C197934379 @default.
• W2893361531 hasConceptScore W2893361531C203092338 @default.

• next